肥大细胞糜酶-1在慢阻肺中的不良作用
该研究检测了慢阻肺患者肺组织中hCMA1水平,并用mmcp5基因缺陷小鼠评估该蛋白酶在香烟烟雾诱导的实验性慢阻肺中的作用及治疗靶向潜力,结合离体/体外研究探讨机制。结果显示hCMA1 mRNA及CMA1+肥大细胞在重度慢阻肺患者肺组织中增多,mmcp5缺陷小鼠对香烟烟雾诱导的炎症、气道重塑、肺气肿及肺功能损害受保护,CMA1抑制剂可抑制这些特征。
要点
- 重度慢阻肺患者肺组织hCMA1 mRNA与CMA1+肥大细胞较早期/轻度患者、非慢阻肺吸烟者及健康对照增多
- mmcp5缺陷小鼠对香烟烟雾诱导的慢阻肺特征性改变受保护
- CMA1/mMCP5部分通过诱导肺巨噬细胞释放TNF-α促进慢阻肺发病,抑制hCMA1可能是新治疗方向
核心结论
- CMA1/mMCP5促进慢阻肺发病,部分通过诱导肺巨噬细胞TNF-α表达与释放实现。
- 抑制hCMA1可能是慢阻肺的新型治疗策略。
研究设计与样本
- 评估慢阻肺患者肺组织中hCMA1水平。
- 使用mmcp5缺陷(-/-)小鼠评估该蛋白酶在香烟烟雾诱导实验性慢阻肺中的作用及治疗靶向潜力。
- 采用离体/体外研究界定机制。
主要发现
- 重度慢阻肺患者肺组织中hCMA1 mRNA水平及CMA1+肥大细胞较早期/轻度慢阻肺患者、非慢阻肺吸烟者和健康对照增加。
- 野生型实验性慢阻肺小鼠肺组织中脱颗粒肥大细胞数和mMCP5蛋白增加。
- mmcp5 -/-小鼠对香烟烟雾诱导的炎症与巨噬细胞聚集、气道重塑、肺气肿及肺功能损害受保护。
- 香烟烟雾提取物刺激野生型而非mmcp5 -/-小鼠肥大细胞与野生型肺巨噬细胞共培养可增加TNF-α释放。
- 香烟烟雾提取物可致人肥大细胞释放CMA1,重组hCMA-1可诱导人巨噬细胞释放TNF-α;CMA1抑制剂可强效抑制实验性慢阻肺的这些标志性特征。
临床怎么用
- 提示hCMA1可能作为慢阻肺治疗靶点,但尚处实验研究阶段,未提供临床用药方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COPD is the third leading cause of death worldwide. Cigarette smoke (CS)-induced chronic inflammation inducing airway remodelling, emphysema and impaired lung function is the primary cause. Effective therapies are urgently needed. Human chymase (hCMA)1 and its orthologue mCMA1/mouse mast cell protease (mMCP)5 are exocytosed from activated mast cells and have adverse roles in numerous disorders, but their role in COPD is unknown. METHODS: We evaluated hCMA1 levels in lung tissues of COPD patients. We used mmcp5-deficient (-/-) mice to evaluate this protease's role and potential for therapeutic targeting in CS-induced experimental COPD. In addition, we used ex vivo/in vitro studies to define mechanisms. RESULTS: The levels of hCMA1 mRNA and CMA1+ mast cells were increased in lung tissues from severe compared to early/mild COPD patients, non-COPD smokers and healthy controls. Degranulated mast cell numbers and mMCP5 protein were increased in lung tissues of wild-type mice with experimental COPD. mmcp5 -/- mice were protected against CS-induced inflammation and macrophage accumulation, airway remodelling, emphysema and impaired lung function in experimental COPD. CS extract challenge of co-cultures of mast cells from wild-type, but not mmcp5 -/- mice with wild-type lung macrophages increased in tumour necrosis factor (TNF)-α release. It also caused the release of CMA1 from human mast cells, and recombinant hCMA-1 induced TNF-α release from human macrophages. Treatment with CMA1 inhibitor potently suppressed these hallmark features of experimental COPD. CONCLUSION: CMA1/mMCP5 promotes the pathogenesis of COPD, in part, by inducing TNF-α expression and release from lung macrophages. Inhibiting hCMA1 may be a novel treatment for COPD.
引用
- Liu G, Jarnicki AG, Paudel KR, et al. Adverse roles of mast cell chymase-1 in COPD. Eur Respir J. 2022. PMID: 35777766. doi:10.1183/13993003.01431-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。